It is known to bind both the GLP-1 receptor and the glucagon receptor, but it is not known whether the effects of the hormone are mediated through these receptors or through an unidentified receptor.
peptide | glucagon | Peptide YY | Peptide mass fingerprinting | Peptide bond | Peptide | Opioid peptide | Glucagon-like peptide-2 | Glucagon-like peptide-1 | Brain natriuretic peptide | Beta-peptide |
The scope of practice includes performing semi-automated external defibrillation, interpretation of 4-lead ECG's, administration of Symptom Relief Medications for a variety of emergency medical conditions (these include oxygen, epinephrine, dextrose, glucagon, salbutamol, ASA and nitroglycerine), performing trauma immobilization (including cervical immobilization), and other fundamental basic medical care.
Some of these pathways include Rap, Erk1/2, MAPK, B-RAF, PI3-K, cAMP, PKA, and TORC2 that are activated to initiate exocytosis, proinsulin gene expression and translation, increase insulin biosynthesis, and genetically increase beta cell proliferation and neogenesis.
Glucagon-like peptide-2 (GLP2) is a 33-amino acid proglucagon-derived peptide produced by intestinal enteroendocrine cells.
GSK716155 (Albugon) is a recombinant human glucagon-like peptide (GLP)-1-Albumin protein created using Human Genome Sciences' proprietary albumin fusion technology, which involves fusing the gene that expresses human albumin to the gene that expresses a therapeutically active protein (GLP-1)1.
IDE, which migrates at 110 kDa during gel electrophoresis under denaturing conditions, has since been shown to have additional substrates, including the signaling peptides glucagon, TGF alpha, and β-endorphin.